The science of laboratory and project management in regulated bioanalysis

Papers of special note have been highlighted as: • of interest

References

• 1 Berman J, Halm K, Adkison K, Shaffer J. Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput. J. Med. Chem. 40, 827–829 (1997).
  Medline CASGoogle Scholar
• 2 Wu JT, Zeng H, Qian M, Brogdon BL, Unger SE. Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. Anal. Chem. 72, 61–67 (2000).
  Medline CASGoogle Scholar
• 3 Watson J, Wright S, Lucas A et al. Receptor occupancy and brain free fraction. Drug Metab. Dispos. 37(4), 753–760 (2009).
  Medline CASGoogle Scholar
• 4 Chernet E, Martin LJ, Li D et al. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples. Life Sci. 78, 340–346 (2005).
  Medline CASGoogle Scholar
• 5 Zhang D, Raghavan N, Chando T et al. LC-MS/MS-based approach to obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab. Lett. 1(4), 293–298 (2007).
  Medline CASGoogle Scholar
• 6 Espina R, Yu L, Wang J et al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 22, 299–310 (2009).
  Medline CASGoogle Scholar
• 7 ICH Guidance M3(R2). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. June 2009. CPMP/ICH/286/95. www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf  
  Google Scholar
• 8 US FDA. Guidance for Industry: Safety Testing of Drug Metabolites. February 2008. www.fda.gov/OHRMS/DOCKETS/98fr/FDA-2008-D-0065-GDL.pdf
  Google Scholar
• 9 Dierks EA, Stams KR, Lim HK et al. A method for the simultaneous evaluation of the activities of seven major human drug metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Met. Disp. 29, 23–29 (2001).
  Medline CASGoogle Scholar
• 10 Turpault S, Brian W, van Horn R et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Brit. J. Clin. Pharmacol. 68(6), 928–935 (2009).
  Medline CASGoogle Scholar
• 11 Gehrig A-K, Mikus G, Haefeli WE, Burhenne J. Electrospray tandem mass spectroscopic characterization of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. Rapid Commun. Mass Spectrom. 21, 2704–2716 (2007).
  Medline CASGoogle Scholar
• 12 Elens L, Veriter S, Yombi JC et al. Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. J. Chromatogr. B 877, 1805–1814 (2009).
  Medline CASGoogle Scholar
• 13 Woosley RL, Cossman J. Drug development and the FDA's critical path initiative. Clin. Pharmacol. Ther. 81, 129–133 (2007).
  Medline CASGoogle Scholar
• 14 Lindon JC, Nicholson JK, Holmes E et al. Contemporary issues in toxicology: The role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol. 187, 137–146 (2003).• Innovation that has the potential to accelerate drug development.
  Medline CASGoogle Scholar
• 15 Wilson ID, Plumb R, Granger J et al. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B 817, 67–76 (2005).
  Medline CASGoogle Scholar
• 16 Reyzer ML, Caprioli RM. MALDI-MS-based imaging of small molecules and proteins in tissues. Curr. Opinion Chem. Biol. 11(1), 29–35 (2007).• Innovation that has the potential to accelerate drug development.
  Medline CASGoogle Scholar
• 17 Wisemana JM, Ifa DR, Zhu Y et al. Desorption electrospray ionization mass spectrometry: imaging drugs and metabolites in tissues. Proc. Natl Acad. Sci. USA 105(47), 18120–18125 (2008).
  MedlineGoogle Scholar
• 18 Mutlib AE, Gerson RJ, Meunier PC et al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol. Appl. Pharmacol. 169, 102–113 (2000).
  Medline CASGoogle Scholar
• 19 Brice RW, Zhang X, Colon LA. Fused-core, sub-2 μm packings, and monolithic HPLC columns: a comparative evaluation. J. Sep. Sci. 32(15–16), 2723–2731 (2009).
  Medline CASGoogle Scholar
• 20 Cunliffe JM. Fast chromatography in the regulated bioanalytical environment: sub-2-μm versus fused-core particles. Bioanalysis 4(8), 861–863 (2012).
  CASGoogle Scholar
• 21 Alpert AJ. Hydrophilic-interaction chromatography for the separation of peptides, nucleic acids and other polar compounds. J. Chromatogr. 499, 177–196 (1990).
  Medline CASGoogle Scholar
• 22 Jandera P. Stationary and mobile phases in hydrophilic interaction chromatography: a review. Anal. Chim. Acta 692(1–2), 1–25 (2011).
  Medline CASGoogle Scholar
• 23 Spooner N, Lad R, Barfield M. Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: Considerations for the validation of a quantitative bioanalytical method. Anal. Chem. 81, 1557–1563 (2009).
  Medline CASGoogle Scholar
• 24 Nowatzke W, Cole TG, Bowsher RR. Systematic analytical validation of commercial kits for the determination of novel biomarkers for clinical drug development. Bioanalysis 2(2), 237–247 (2010).
  CASGoogle Scholar
• 25 Kondrat R, Cooks R Direct analysis of mixtures by mass spectrometry. Anal. Chem. 50, 81A–92A (1978).
  CASGoogle Scholar
• 26 Paul W, Reinhard HP, Zahn O. The electric mass filter as mass spectrometer and isotope separator. Zeitschrift fuer Physik 152, 143–182 (1958).
  CASGoogle Scholar
• 27 Dawson PH. Quadrupole Mass Spectrometry and Its Applications. Elsevier, Amsterdam, The Netherlands (1976).
  Google Scholar
• 28 Yost RA, Enke CG. Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation. Anal. Chem. 51(12), 1251A–1262A (1979).
  Medline CASGoogle Scholar
• 29 Reid N M, Buckley JA, Poon CC, French JB. TAGA 3000: a new, multipurpose, digitally controlled atmospheric pressure chemical ionization mass spectrometer based system. Adv. Mass Spectrom. 8B, 1843–1850 (1980).
  CASGoogle Scholar
• 30 Bruins AP. Liquid chromatography-mass spectrometry with ionspray and electrospray interfaces in pharmaceutical and biomedical research. J. Chromatogr. 554(1–2), 39–46 (1991).
  Medline CASGoogle Scholar
• 31 Thomson B, Iribarne J, Dziedzic P. Liquid ion evaporation/mass spectrometry/mass spectrometry for the detection of polar and labile molecules. Anal. Chem. 54, 2219–2224 (1982).
  CASGoogle Scholar
• 32 Covey T, Lee E, Henion J. High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples. Anal. Chem. 58, 2453–2460 (1986).
  Medline CASGoogle Scholar
• 33 Moseley MA, Unger SE. Packed column liquid chromatography/electrospray ionization/mass spectrometry in the pharmaceutical sciences: characterization of protein mixtures. J. Microcol. 4, 393–398 (1992).
  CASGoogle Scholar
• 34 Bruins AP, Covey TR, Henion JD. Ion spray interface for combined liquid chromatography/atmospheric pressure ionization mass spectrometry. Anal. Chem. 59(22), 2642–2646 (1987).
  CASGoogle Scholar
• 35 Wu JT, Zeng H, Deng Y, Unger SE. High-speed liquid chromatography/tandem mass spectrometry using a monolithic column for high-throughput bioanalysis. Rapid Commun. Mass Spectrom. 15, 1113–1119 (2001).
  Medline CASGoogle Scholar
• 36 Fenn J, Mann M, Meng C et al. Electrospray ionization, principles and practice. Mass Spectrom. Rev. 9, 37–70 (1990).
  CASGoogle Scholar
• 37 Rainville P. Microfluidic LC–MS for analysis of small-volume biofluid samples: where we have been and where we need to go. Bioanalysis 3(1), 1–3 (2011).
  CASGoogle Scholar
• 38 Stafford Jr GC, Kelley PE, Syka JEP et al. Recent improvements in and analytical applications of advanced ion trap technology. Int. J. Mass Spectrom. Ion Proc. 60, 85–98 (1984).
  CASGoogle Scholar
• 39 Schwartz JC, Senko MW, Syka JEP. A two-dimensional quadrupole ion trap mass spectrometer. J. Am. Soc. Mass Spectrom. 13(6), 659–669 (2002).• Innovation that has the potential to accelerate drug development.
  Medline CASGoogle Scholar
• 40 Leuthold LA, Grivet C, Allen M et al. Simultaneous selected reaction monitoring, MS/MS and MS3 quantitation for the analysis of pharmaceutical compounds in human plasma using chip-based infusion. Rapid Commun. Mass Spectrom. 18(17), 1995–2000 (2004).
  Medline CASGoogle Scholar
• 41 Kapron JT, Jemal M, Duncan G, Kolakowski B, Purves R. Removal of metabolite interference during liquid chromatography/tandem mass spectrometry using high-field asymmetric waveform ion mobility spectrometry. Rapid Commun. Mass Spectrom. 19(14), 1979–1983 (2005).
  CASGoogle Scholar
• 42 Schneider BB, Covey TR, Coy SL et al. Chemical effects in the separation process of a differential mobility/mass spectrometer system. Anal. Chem. 82(5), 1867–1880 (2010).• Innovation that has the potential to accelerate drug development.
  Medline CASGoogle Scholar
• 43 Unger SE. Isomer differentiation in fast atom bombardment mass spectrometry/mass spectrometry. Int. J. Mass Spectrom. Ion Proc. 66, 195–208 (1985).
  CASGoogle Scholar
• 44 MacNair JE, Patel KD, Jorgenson JW. Ultrahigh-pressure reversed-phase capillary liquid chromatography: isocratic and gradient elution using columns packed with 1.0-μm particles. Anal. Chem. 71(3), 700–708 (1999).• Innovation that has the potential to accelerate drug development.
  Medline CASGoogle Scholar
• 45 King RC, Miller-Stein C, Magiera DJ, Brann J. Description and validation of a staggered parallel high performance liquid chromatography system for good laboratory practice quantitative analysis by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16, 43–52 (2002).
  Medline CASGoogle Scholar
• 46 Andrews GL, Simons BL, Young J et al. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal. Chem. 83(13), 5442–5446 (2011).
  Medline CASGoogle Scholar
• 47 Makarov A. Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis. Anal. Chem. 72(6), 1156–1162 (2000).• Innovation that has the potential to accelerate drug development.
  Medline CASGoogle Scholar
• 48 Makarov A, Denisov E, Kholomeev A, Balschun W et al. Performance evaluation of a hybrid linear ion trap/orbitrap mass spectrometer. Anal. Chem. 78(7), 2113–2120 (2006).
  Medline CASGoogle Scholar
• 49 Bateman KP, Kellmann M, Muenster H et al. Quantitative-qualitative data acquisition using a benchtop orbitrap mass spectrometer. J. Am. Soc. Mass Spectrom. 20(8), 1441–1450 (2009).
  Medline CASGoogle Scholar
• 50 Wells DA. High Throughput Bioanalytical Sample Preparation: Methods and Automation Strategies. Elsevier, Amsterdam, The Netherlands (2003)
  Google Scholar
• 51 Janiszewski JS, Liston TE, Cole MJ. Perspectives in bioanalytical mass spectrometry and automation in drug discovery. Curr. Drug Metabol. 9, 986–994 (2008).
  Medline CASGoogle Scholar
• 52 Fast, DM, Kelly M, Viswanathan CT et al. Workshop report and follow-up – AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples – implications of Crystal City recommendations. AAPS J. 11, 238–241 (2009).• Guidance under which laboratories must adhere to submit data to regulatory agencies.
  MedlineGoogle Scholar
• 53 Viswanathan CT, Bansal S, Booth B et al. Workshop/conference report – Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. E30–E42 (2007).• Guidance under which laboratories must adhere to submit data to regulatory agencies.
  Google Scholar
• 54 Wang J, Aubry A-F, Cornelius G et al. Importance of mobile phase and injection solvent selection during rapid method development and sample analysis in drug discovery bioanalysis illustrated using convenient multiplexed LC-MS/MS. Anal. Methods 2(4), 375–381 (2010).
  CASGoogle Scholar
• 55 Snyder LR, Glajch JL, Kirkland JJ. Practical HPLC Method Development. John Wiley & Sons, NY, USA (1988).
  Google Scholar
• 56 Bansal SK, Layloff T, Bush ED et al. Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach. AAPS PharmSciTech 5(1), 22 (2004).
  MedlineGoogle Scholar
• 57 Agência Nacional de Vigilância Sanitária (ANVISA). Guide for validation of analytical and bioanalytical methods. European Bioanalysis Forum, Brussels Belgium (2003).
  Google Scholar
• 58 EMA. Guideline on bioanalytical method validation. July 2011. CHMP/EWP/192217/2009. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.• Guidance under which laboratories must adhere to submit data to regulatory agencies.
  Google Scholar
• 59 Hughes NC, Bajaj N, Fan J, Wong EYK. Assessing the matrix effects of hemolyzed samples in bioanalysis. Bioanalysis 1, 1057–1066 (2009).
  CASGoogle Scholar
• 60 Cashman JR. Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem. Res. Toxicol. 89(2), 166–181 (1995).
  Google Scholar
• 61 Ortiz de Montellano PR. Oxygen activation and transfer. In: Cytochrome P-450 Structure, Mechanism and Biochemistry. Ortiz de Montellano PR (Ed.). Plenum Press, NY, USA, 217 (1986).
  Google Scholar
• 62 Berube E-R, Taillon M-P, Futrado M, Garofolo F. Impact of sample hemolysis on drug stability in regulated bioanalysis. Bioanalysis 3, 2097–2105 (2011).
  CASGoogle Scholar
• 63 Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol. Rev. 49, 279–295 (1997).
  Medline CASGoogle Scholar
• 64 Shi G, Lloyd TL, Sy SKB, Jiao Q et al. Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. J. Pharm. Biomed. Appl. 31, 937–951 (2003).
  Medline CASGoogle Scholar
• 65 Shi G, Wu JTLi Y et al. Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass. Spectrom. 16, 1092–1099 (2002).
  Medline CASGoogle Scholar
• 66 Subbarao K, Rucinski B, Rausch MA et al. Binding of dipyridamole to human platelets and to α1 acid glycoprotein and its significance for the inhibition of adenosine uptake. J. Clin. Invest. 60, 936–943 (1977).
  Medline CASGoogle Scholar
• 67 Yu S, Li S, Yang H et al. A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun. Mass Spectrom. 19, 250–254 (2005).
  Medline CASGoogle Scholar
• 68 Brockman AH, Hatsis P, Paton M, Wu JT. Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. Anal. Chem. 79, 1599–1603 (2007).
  Medline CASGoogle Scholar
• 69 Hooks A. Tacrolimus, a new immunosuppressant – a review of the literature. Ann. Pharmacother. 28(4), 501–511 (1994).
  Medline CASGoogle Scholar
• 70 Leung LY, Lim HK, Abell MW, Zimmerman JJ. Pharmacokinetics and metabolic disposition of sirolimus in healthy male volunteers after a single oral dose. Ther. Drug Monit. 28(1), 51–61 (2006).
  Medline CASGoogle Scholar